How to select the optimal therapy for early-stage prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue SUPPL. 1, 2012, Pages e6-e15

  Kollmeier, Marisa A ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; External beam radiotherapy; Prostate cancer; Surgery; Treatment selection

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL DECISION MAKING; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LAPAROSCOPIC SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT REFERRAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; UROGENITAL TRACT DISEASE;

EID: 84871706840     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.002     Document Type: Review

References (60)

1. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
2. Parker C., Muston D., Melia J., et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006, 94:1361-1368.
3. Freedland S.J., Kane C.J., Amling C.L., et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 2006, 175:1298-1302. [discussion 1293-302].
4. Warlick C., Trock B.J., Landis P., et al. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006, 98:355-357.
5. Ng M.K., Van As N., Thomas K., et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009, 103:872-876.
6. Zhang L., Loblaw A., Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006, 176:1392-1397. [discussion 1397-8].
7. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-135.
8. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005, 294:440-447.
9. Oon S.F., Watson R.W., O'Leary J.J., et al. Epstein criteria for insignificant prostate cancer. BJU Int 2011.
10. Jeldres C., Suardi N., Walz J., et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008, 54:1306-1313.
11. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007, 99:786-793.
12. Nogueira L., Wang L., Fine S.W., et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 2010, 75:472-477.
13. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305.
14. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
15. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
16. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25:4178-4186.
17. Vickers A., Savage C., Bianco F., et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol 2011, 59:317-322.
18. Zelefsky M.J., Yamada Y., Pei X., et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011, 77:986-990.
19. Vassil A.D., Murphy E.S., Reddy C.A., et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010, 76:1251-1257.
20. Coen J.J., Zietman A.L., Rossi C.J., et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 2011.
21. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
22. Pisansky T.M., Gold D.G., Furutani K.M., et al. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc 2008, 83:1364-1372.
23. Pieters B.R., de Back D.Z., Koning C.C., et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009, 93:168-173.
24. King C.R., Brooks J.D., Gill H., et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective Phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048.
25. Ghadjar P., Keller T., Rentsch C.A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
26. Corner C., Rojas A.M., Bryant L., et al. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:441-446.
27. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
28. Kovacs G., Potter R., Loch T., et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 2005, 74:137-148.
29. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160:1379-1382.
30. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73:1023-1032.
31. Moran B.J., Stutz M.A., Gurel M.H. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004, 59:392-396.
32. Willett C.G., Ooi C.J., Zietman A.L., et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 2000, 46:995-998.
33. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004, 64:754-759.
34. Burri R.J., Ho A.Y., Forsythe K., et al. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:1315-1321.
35. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
36. Pardo Y., Guedea F., Aguilo F., et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010, 28:4687-4696.
37. Pinkawa M., Asadpour B., Piroth M.D., et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer-a matched-pair comparison. Radiother Oncol 2009, 91:225-231.
38. Love A.W., Scealy M., Bloch S., et al. Psychosocial adjustment in newly diagnosed prostate cancer. Aust N Z J Psychiatry 2008, 42:423-429.
39. Jayadevappa R., Johnson J.C., Chhatre S., et al. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer 2007, 109:2229-2238.
40. Do Y.K., Carpenter W.R., Spain P., et al. Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control 2010, 21:31-40.
41. Stone N.N., Stone M.M., Rosenstein B.S., et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011, 185:495-500.
42. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
43. Dattoli M., Wallner K., True L., et al. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol 2010.
44. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
45. Sylvester J.E., Grimm P.D., Wong J., et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: seattle experience. Int J Radiat Oncol Biol Phys 2010.
46. Alicikus Z.A., Yamada Y., Zhang Z., et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437.
47. Birkhahn M., Penson D.F., Cai J., et al. Long-term outcome in patients with a Gleason score
48. Tanaka N., Fujimoto K., Hirayama A., et al. Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol 2011.
49. Klein E.A., Bianco F.J., Serio A.M., et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008, 179:2212-2216. [discussion 2216-7].
50. Pierorazio P.M., Guzzo T.J., Han M., et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 2010, 76:715-721.
51. Desireddi N.V., Roehl K.A., Loeb S., et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70:950-955.
52. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003, 57:1254-1259.
53. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
54. Tsuji H., Yanagi T., Ishikawa H., et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 2005, 63:1153-1160.
55. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
56. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
57. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66:1072-1083.
58. Lloyd-Davies R.W., Collins C.D., Swan A.V. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology 1990, 36:107-111.
59. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105.
60. Chen R.C., Clark J.A., Talcott J.A. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009, 27:3916-3922.